Tacrolimus for Idiopathic nephrotic syndrome

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-10000945

Enrollment

Unknown

Registered

2010-07-15

Start date

2009-06-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic nephrotic syndrome

Interventions

A:Cycrosporin + Glucocorticoids

B:Cap. Tacrolimus + Glucocorticoids

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. consistent with primary renal disease, and sign comprehensive diagnostic criteria and confirmed by renal biopsy pathology. After 8-12 weeks of prednisone treatment in sufficient quantities, the result is invalid or treatment in a relapse state, or steroid-dependent; 2. aged 18-60 years.

Exclusion criteria

Exclusion criteria: 1. secondary renal comprehensive and sign; 2. had received cyclophosphamide (CTX), mycophenolate mofetil, cyclosporin A, Hook, leflunomide and other drug treatment (more than 1 week) in last 3 months; 3. serum creatinine> 265umol/L; 4. with severe complications such as severe infection, pulmonary embolism and so on; 5. sustained abnormal liver function, ALT or AST 2 times upper limit of normal, or HBsAg, or HCV-Ab positive; 6. abnormal glucose metabolism; 7. pregnant or lactating.

Design outcomes

Primary

Measure	Time frame
Partial remission rate;Side effects;Complete remission rate;	—

Secondary

Measure	Time frame
Serum creatinine;Urine protein;Serum albumin;	—

Countries

China

Contacts

Public ContactChanglin Mei

chlmei1954@126.com+86 021 81885391

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026